Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial
- 1 May 2005
- journal article
- clinical trial
- Published by Elsevier in Lung Cancer
- Vol. 48 (2) , 267-273
- https://doi.org/10.1016/j.lungcan.2004.11.004
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trialLung Cancer, 2004
- Role of cyclooxygenase-2 in the development and treatment of oesophageal adenocarcinomaScandinavian Journal of Gastroenterology, 2003
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung CancerJAMA, 2003
- Lung cancer and cyclooxygenase-2The Annals of Thoracic Surgery, 2003
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Economic Analysis of the TAX 317 Trial: Docetaxel Versus Best Supportive Care as Second-Line Therapy of Advanced Non-Small-Cell Lung CancerJournal of Clinical Oncology, 2002
- Weekly docetaxel as II line therapy in non-small cell lung cancer: an interim analysis of a phase II studyLung Cancer, 2001
- Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinomaCancer, 2001
- Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy RegimensJournal of Clinical Oncology, 2000
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyJournal of Clinical Oncology, 2000